Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nuclear factor related to kappa-B-binding protein (NFRKB)
- Target
- NFRKB
- Molecular classification
- Transcription factor (by sequence homology and chromatin association), Chromatin remodeling protein (INO80 complex component), DNA-binding protein (has a winged-helix DNA interaction motif)
01
Overview
Nuclear factor related to kappa-B-binding protein (NFRKB) is a protein-coding gene encoding a metazoan-specific subunit of the INO80 chromatin remodeling complex. NFRKB binds specific DNA sequences (5'-GGGGAATCTCC-3'), and acts as a regulatory component that modulates transcriptional regulation, DNA replication, and repair—especially telomere maintenance and stability. In cancer biology, particularly hepatocellular carcinoma, NFRKB is highly expressed and accumulates in tumor nuclei but is lower in normal hepatocytes. Its increased levels correlate with poor clinical outcomes. Pathway analysis links NFRKB to transcription-coupled nucleotide excision repair and protein metabolism. NFRKB also influences the activity of the deubiquitinase UCHL5 within the INO80. No drugs currently modulate NFRKB directly, but its prognostic value highlights its biological and therapeutic interest, particularly in oncology
- Other names
- INO80GINO80 complex subunit GDNA-binding protein R kappa BDKFZp547B2013Nuclear factor related to kappa B binding proteinDNA-binding protein R kappa-B
02
Mechanism of action
None established; NFRKB is not a direct target of any approved drugs. Its relevance currently lies in its role as a biomarker and as a regulatory protein in chromatin remodeling
03
Biological functions
Chromatin remodelingRegulation of chromosome organizationRegulation of nucleobase-containing metabolic processTranscriptional regulationDNA replicationDNA repair (especially associated with telomere protection and stability)Modulates deubiquitinase activity of UCHL5 within the INO80 complex
04
Disease associations
Cancer (particularly hepatocellular carcinoma, where overexpression predicts poor prognosis)Fanconi anemia (complementation group I)High-grade B-cell lymphoma double-hit/triple-hit
05
Safety considerations
None specifically reported, as there are no drugs directly targeting NFRKB. Safety concerns would depend on off-target or downstream chromatin effects if modulated pharmacologically
06
Biomarkers
High expression predicts poor prognosis in hepatocellular carcinoma (HCC)Putative prognostic biomarker for HCC patient selection
Beyond the preview
Go deeper on Nuclear factor related to kappa-B-binding protein (NFRKB).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nuclear factor related to kappa-B-binding protein (NFRKB).